Filtered By:
Cancer: Carcinoma
Drug: Yervoy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 316 results found since Jan 2013.
Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab
CONCLUSIONS: Our study provides insight into newer mccRCC treatment tolerability and effectiveness in the real-world US community setting. Our real-world results were comparable to data from clinical trials, which is encouraging for mccRCC patients.PMID:37722984 | DOI:10.1016/j.urolonc.2023.08.009
Source: Urologic Oncology - September 18, 2023 Category: Urology & Nephrology Authors: Neil J Shah Sneha D Sura Reshma Shinde Junxin Shi Puneet Singhal Rodolfo F Perini Robert J Motzer Source Type: research
Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases
CONCLUSIONS: The combination of intratumoral vidutolimod, radiosurgery, nivolumab and ipilimumab was not found to be efficacious in MSS mCRC with liver metastases. The juxtaposition of liver irradiation and intratumoral vidutolimod injection was associated with high hepatic toxicity.PMID:37657954 | DOI:10.1016/j.clcc.2023.08.004
Source: Clinical Colorectal Cancer - September 1, 2023 Category: Cancer & Oncology Authors: Ofer Margalit Sivan Lieberman Ilanit Redinsky Sharon Halparin Nir Honig Stephen Raskin Maoz Ben-Ayun Einat Shacham-Shmueli Naama Halpern Damien Urban Aliza Ackerstein Katerina Shulman Eytan Ben-Ami Valeriya Semenisty Ofer Purim Nirit Yarom Talia Golan Ben Source Type: research
Presentation of new onset type 1 diabetes with diabetic ketoacidosis and hyperosmolar hyperglycaemia after a single dose of nivolumab and ipilimumab
Endocrinol Diabetes Metab Case Rep. 2023 Aug 16;2023(3):22-0389. doi: 10.1530/EDM-22-0389. Print 2023 Aug 1.ABSTRACTSUMMARY: A Caucasian man in his 60s with recent diagnosis of metastatic renal cell carcinoma presented to the emergency department with a 5-day history of severe polyuria, polydipsia and fatigue and 1-day history of confusion, abdominal pain, nausea and vomiting. Investigations revealed an overlap of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycaemic state (HHS). He had received the first dose of immunotherapy with nivolumab and ipilimumab 3 weeks prior to this attendance. New-onset type 1 diabetes (...
Source: Cancer Control - August 16, 2023 Category: Cancer & Oncology Authors: Dimitra Stathi Sufyan Hussain Danielle Crawley Janaka Karalliedde Source Type: research
Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma
CONCLUSION: Latinx patients with mRCC had a shorter PFS treated with frontline nivolumab/ipilimumab compared to their non-Latinx counterparts. No difference was observed in OS although these data were immature. Larger studies are needed to further interrogate the social and economic determinants of ethnicity on clinical outcomes in mRCC.PMID:37432304 | DOI:10.1093/oncolo/oyad190
Source: The Oncologist - July 11, 2023 Category: Cancer & Oncology Authors: Alexander Chehrazi-Raffle Sally Leong Sana Ali Tane Kim Sam Melamed Xiaochen Li Zeynep Zengin Luis Meza Neal Chawla Ameish Govindarajan Daniela Castro Benjamin Mercier Hedyeh Ebrahimi Nazli Dizman Nishita Tripathi Nicolas Sayegh Adam Rock James Yeh Sumant Source Type: research
A Podcast Discussion on the Current Treatment Landscape for Renal Cell Carcinoma
Adv Ther. 2023 Jul 12. doi: 10.1007/s12325-023-02569-z. Online ahead of print.ABSTRACTDuring the last 15 years, tremendous efforts have been made in the medical treatment of metastatic renal cell carcinoma (mRCC). Immune-oncological (IO) combinations are the current standard of care in the first-line setting of mRCC. Here, the current phase 3 trials CM214 (nivolumab/ipilimumab vs. sunitinib), KN426 (axitinib/pembrolizumab vs. sunitinib), Javelin-ren-101 (axitinib/avelumab vs. sunitinib), CM9ER (cabozantinib/nivolumab vs. sunitinib), and CLEAR (lenvatinib/pembrolizumab vs. sunitinib) were discussed. In the mentioned phase 3...
Source: Adv Data - July 11, 2023 Category: Epidemiology Authors: Philipp Ivanyi Jonas Paul Wiegmann Hendrik Eggers Viktor Gr ünwald Source Type: research
Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma
CONCLUSION: Latinx patients with mRCC had a shorter PFS treated with frontline nivolumab/ipilimumab compared to their non-Latinx counterparts. No difference was observed in OS although these data were immature. Larger studies are needed to further interrogate the social and economic determinants of ethnicity on clinical outcomes in mRCC.PMID:37432304 | DOI:10.1093/oncolo/oyad190
Source: The Oncologist - July 11, 2023 Category: Cancer & Oncology Authors: Alexander Chehrazi-Raffle Sally Leong Sana Ali Tane Kim Sam Melamed Xiaochen Li Zeynep Zengin Luis Meza Neal Chawla Ameish Govindarajan Daniela Castro Benjamin Mercier Hedyeh Ebrahimi Nazli Dizman Nishita Tripathi Nicolas Sayegh Adam Rock James Yeh Sumant Source Type: research
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial
CONCLUSIONS: Nivolumab monotherapy demonstrated an acceptable safety profile and objective activity, although it has been insufficient to meet its primary objective. The second cohort of NIVOTHYM is currently ongoing to assess the combination of nivolumab plus ipilimumab.PMID:37285717 | DOI:10.1016/j.esmoop.2023.101576
Source: Cancer Control - June 7, 2023 Category: Cancer & Oncology Authors: N Girard S Ponce Aix S Cedres T Berghmans S Burgers A-C Toffart S Popat A Janssens R Gervais M Hochstenbag M Silva I A Burger H Prosch R Stahel E Xenophontos Y Pretzenbaher A Neven S Peters Source Type: research
Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab
CONCLUSIONS: Low SMI and low SATI were associated with significantly better PFS for patients with mRCC receiving first-line ipi/nivo. Radiographic BC variables may be useful prognostic biomarkers in this setting.PMID:37271698 | DOI:10.1016/j.clgc.2023.05.006
Source: Clinical Prostate Cancer - June 4, 2023 Category: Cancer & Oncology Authors: Hannah D McManus Dylan Zhang Fides R Schwartz Yuan Wu Jordan Infield Ethan Ho Andrew J Armstrong Daniel J George Danielle Kruse Rajan T Gupta Michael R Harrison Source Type: research
Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?
We present ongoing trials with an adaptive design that may serve as alternative methods for escalating from doublet to triplet regimens in the frontline setting and explore clinical factors and emerging predictive biomarkers (both baseline and dynamic) that may guide future trial design and frontline treatment for patients with advanced ccRCC.PMID:37207297 | DOI:10.1200/EDBK_389650
Source: Cancer Control - May 19, 2023 Category: Cancer & Oncology Authors: Catherine C Fahey Jeffrey W Shevach Ronan Flippot Laurence Albiges Naomi B Haas Kathryn E Beckermann Source Type: research
Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances
Pathol Res Pract. 2023 Apr 20;246:154470. doi: 10.1016/j.prp.2023.154470. Online ahead of print.ABSTRACTThe immune system uses various immune checkpoint axes to adjust responses, support homeostasis, and deter self-reactivity and autoimmunity. Nevertheless, non-small-cell lung carcinoma (NSCLC) can use protective mechanisms to facilitate immune evasion, which leads to potentiated cancer survival and proliferation. In this light, many blocking anti-bodies have been developed to negatively regulate checkpoint molecules, in particular, programmed cell death protein 1 (PD-1) / PD-ligand 1 (L1), and bypass these immune suppress...
Source: Pathology, Research and Practice - May 7, 2023 Category: Pathology Authors: Tannaz Dehghani Alireza Shahrjerdi Mohammad Saeed Kahrizi Elnaz Soleimani Saeideh Ravandeh Muna S Merza Negin Rahnama Farnoosh Ebrahimzadeh Morteza Bakhshesh Source Type: research
